lutein · zeaxanthin · meso-zeaxanthin · macular pigments · carotenoids
25 mg · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Lutein and zeaxanthin are carotenoid pigments that accumulate in the macula of the retina, where they filter blue light, scavenge free radicals, and protect photoreceptors from oxidative damage. They are found in dark leafy greens, egg yolks, and colorful vegetables.
Lutein and zeaxanthin form the macular pigment, which absorbs high-energy blue light before it damages photoreceptors. They also quench reactive oxygen species in the retina and may improve visual contrast sensitivity and glare recovery.
Adults over 50 at risk for AMD, individuals with family history of macular degeneration, those with low dietary intake of leafy greens, people seeking eye health protection.
People with carotenoid absorption disorders (rare), those taking beta-carotene supplements (may compete for absorption), smokers (beta-carotene increased lung cancer risk in smokers; lutein/zeaxanthin data is neutral but caution warranted).
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Morning with breakfast for consistent absorption
✓ Fat-containing meal essential for carotenoid absorption
Lutein and zeaxanthin form the macular pigment, which absorbs high-energy blue light before it damages photoreceptors.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Representative cohort from published RCT data
Relative to baseline (100). Data from published clinical literature.
see study
→ AREDS2: lutein/zeaxanthin reduced risk of advanced AMD by 18% vs beta-carotene; no cardiovascular risk (N=4,203, 5 years)
see study
→ Meta-analysis: high dietary lutein/zeaxanthin associated with 26% reduced risk of late AMD (N=multiple cohorts)
see study
→ Original AREDS observational data: high lutein/zeaxanthin intake associated with 43% reduced AMD risk (N=356)
A · AREDS2 is the largest eye supplement trial ever conducted; lutein/zeaxanthin outperformed beta-carotene; no cardiovascular risk; dietary and supplemental evidence converges; FDA allows qualified health claim
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: See richResearch section for study filters and participant data. Clinical evidence summarised from peer-reviewed journals.
How to use Lutein + Zeaxanthin specifically for blurred vision — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Lutein + Zeaxanthin — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Lutein + Zeaxanthin — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Lutein + Zeaxanthin — context the structured blocks above don't capture.
Lutein and zeaxanthin are the gold standard for evidence-based eye supplementation. Unlike most supplements that rely on small trials or mechanistic extrapolation, these carotenoids have been tested in the largest eye health trial ever conducted—the Age-Related Eye Disease Study 2 (AREDS2)—and demonstrated genuine efficacy in reducing progression of age-related macular degeneration (AMD), the leading cause of blindness in older adults. This is not theoretical benefit; it is hard clinical outcome data from a randomized controlled trial funded by the National Institutes of Health.
The AREDS2 trial was definitive. Chew and colleagues (2013, JAMA, PMID 23644932) randomized 4,203 participants with intermediate AMD to lutein 10 mg + zeaxanthin 2 mg, omega-3 fatty acids, both, or placebo for 5 years. The lutein/zeaxanthin group reduced the risk of progression to advanced AMD by 18% compared to the original AREDS formula containing beta-carotene. This substitution was critical: beta-carotene had increased lung cancer risk in smokers, while lutein/zeaxanthin showed no such risk. The FDA now allows a qualified health claim for lutein/zeaxanthin and AMD risk reduction.
The observational evidence converges with trial data. Seddon and colleagues (1994, JAMA, PMID 8002842) established the original dietary association, finding that high intake of lutein/zeaxanthin was associated with 43% reduced risk of advanced AMD in the initial AREDS cohort. Ma and colleagues (2012, British Journal of Nutrition, PMID 22348989) conducted a meta-analysis of multiple cohort studies and confirmed that high dietary intake was associated with 26% reduced risk of late AMD. The consistency across dietary studies, biomarker studies, and randomized trials creates a robust evidentiary chain.
The mechanism is biologically plausible and well-characterized. Lutein and zeaxanthin accumulate in the macula, where they form a yellow pigment that filters high-energy blue light before it reaches photoreceptors. They also quench reactive oxygen species generated by retinal metabolism. The macular pigment optical density (MPOD) can be measured non-invasively, and supplementation consistently increases MPOD in a dose-dependent manner. The honest framing: lutein and zeaxanthin are the most evidence-based eye supplements available, with NIH trial validation, FDA health claim status, and a well-characterized mechanism. They are appropriate for anyone over 50 with AMD risk factors or family history.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
